1038924-71-8

Basic information

• Product Name: (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride
• Synonyms: (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride;(2R,4S)-4-Amino-4-([1,1'-biphenyl]-4-ylmethyl)-2-methylbutanoic acid hydrochloride(1:1);LCA696 impurity;LCZ701;LCZ-696 Impurity 2;Sacubitril Impurity 11 HCl
• CAS NO: 1038924-71-8
• Molecular Formula: C₁₈H₂₁NO₂*ClH
• Molecular Weight: 319.82578
• Product Categories: LCZ696
• Mol File: 1038924-71-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride(1038924-71-8)
• EPA Substance Registry System: (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride(1038924-71-8)

Safety Data

• Hazardous Substances Data: 1038924-71-8(Hazardous Substances Data)

Usage

Description

(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride is a complex organic compound characterized by its unique molecular structure, featuring a biphenyl group and an amino acid backbone. (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride is known for its role as a building block in the synthesis of various pharmaceuticals and chemicals.

Uses

Used in Pharmaceutical Synthesis:
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride is used as a building block in the chemical synthesis of various pharmaceuticals. Its unique structure allows for the creation of complex molecules with specific therapeutic properties.
Used in the Synthesis of Antihypertensive Drugs:
Specifically, (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride is utilized in the synthesis of Sacubitri (S080900), an antihypertensive drug. (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride contributes to the development of medications that help regulate blood pressure, providing a valuable application in the treatment of hypertension.

Upstream product

• 182680-37-1 4-(2-nitroethyl)-1,1'-biphenyl 
• 3218-36-8 4-Phenylbenzaldehyde 
• 263551-29-7 (E)-4-(2-nitrovinyl)-1,1'-biphenyl 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1038924-70-7 (3R,5S)-5-({[1,1'-biphenyl]-4-yl}methyl)-3-methylpyrrolidin-2-one 
• 1038924-66-1 (3R,5S)-5-biphenyl-4-ylmethyl-1-(2,2-dimethylpropionyl)-3-methylpyrrolidin-2-one 
• 64-17-5 ethanol 

Downstream Products

• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 752174-62-2 (2R,4S)-4-amino-5-biphenyl-4-yl-2-methylpentanoic acid ethyl ester 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 

Relevant articles and documents

Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.

Diastereoselective Synthesis of an Industrially Relevant 4-Aminopentanoic Acid by Asymmetric Catalytic Hydrogenation in a Biphasic System Using Aqueous Sodium Hydroxide as Substrate Phase

A 'basic solution' for multiphase catalysis: The diastereoselective synthesis of a pharmaceutically relevant 4-aminopentanoic acid derivative has been studied using a chiral homogeneous catalyst in tailored biphasic reaction media. Different polar solvents were investigated as the stationary phase for the well-established Ru-Mandyphos catalyst in combination with aqueous NaOH as the substrate and product phase. Facile product isolation and effective recycling of the catalyst phase were demonstrated at gram-scale. In particular, up to 3200 turnovers have been achieved in seven repetitive batches with a diastereoselectivity of 87-96% using [EMIM][NTf2]/NaOHaq as the biphasic system.

NEW PROCESS

The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new chemical synthesis